Clinical Trials Logo

Filter by:
NCT ID: NCT05352022 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

Lowering Food Insecurity and Improving Diabetes With Financial Incentives

LIFT-FINANCE
Start date: May 1, 2022
Phase: N/A
Study type: Interventional

The overarching aim of this proposal is to test the efficacy of financial incentives in improving HbA1c, blood pressure, and quality of life in food insecure adults with poorly controlled type 2 diabetes. Using a clinical trial design, the investigators will randomize food insecure adults with type 2 diabetes to one of three financial incentive structures in combination with monthly mailings that will include diabetes education, healthy recipes, and meal planning resources.

NCT ID: NCT05351801 Active, not recruiting - Clinical trials for Diabetic Neuropathic Pain

Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain

Start date: June 21, 2023
Phase: Phase 2
Study type: Interventional

Veterans with diabetes are more likely than diabetic civilians to develop disabling chronic diabetic neuropathic pain (CDNP). Research on frontline treatments for CDNP (enhanced glycemic control, exercise, pharmacological agents), shows inconsistent outcomes and dissatisfaction among Veterans. Veterans and clinicians have shown significant interest in cannabis derivatives (THC, CBD) for neuropathic pain control, but there are no well-controlled trials guiding expectations for benefit and adverse outcomes associated with cannabis for CDNP. Because Veterans are likely to present with pain and pain-related polymorbidity significantly differing from that of civilians, a well-structured clinical trial of cannabinoids for Veterans with CDNP is vital. The present phase II study will offer the first evidence describing the potential benefits and adverse effects of cannabinoids for CDNP in Veterans using a four-arm, double-blind, multisite randomized trial comparing THC, CBD, THC+CBD and placebo on neuropathic pain outcomes.

NCT ID: NCT05351710 Active, not recruiting - Perfectionism Clinical Trials

A Randomized Controlled Trial of an Exposure-Based Treatment for Perfectionism

Start date: August 30, 2022
Phase: N/A
Study type: Interventional

This study is examining the efficacy of a computerized, exposure-based, intervention for perfectionism.

NCT ID: NCT05351580 Active, not recruiting - Parkinson Disease Clinical Trials

DiSCERN: Advanced PD Therapy Candidacy and Evaluation System

DiSCERN
Start date: July 21, 2022
Phase:
Study type: Observational

To collect data to develop models that identify when patients with advanced Parkinson's disease (PD) are not responding well to their current therapy and may be ready to consider advanced therapy and when patients receiving advanced therapy are not responding well and need a therapy adjustment.

NCT ID: NCT05351255 Active, not recruiting - Cerebellar Ataxia Clinical Trials

Motor Learning After Cerebellar Damage: The Role of the Primary Motor Cortex

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This study will determine (1) whether baseline inhibitory activity in the primary motor cortex can predict motor learning ability in individuals with cerebellar degeneration, and (2) whether modulating primary motor cortex activity with non-invasive brain stimulation alters motor learning ability in this population.

NCT ID: NCT05351164 Active, not recruiting - Clinical trials for Lipomatosis, Multiple Symmetrical

Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

Patients (homozygous MFN2 [gene that provides instructions to produce the Mitofusin 2 protein] R707W) will be treated with Metreleptin, and effects on body composition, metabolic parameters and safety will be assessed over a 6 month intervention period. Additional safety will be assessed for 1 more year (up to 1.5 years total) in which adverse event data will be collected.

NCT ID: NCT05350163 Active, not recruiting - Myeloid Malignancy Clinical Trials

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

Start date: April 5, 2022
Phase: Phase 1
Study type: Interventional

This pilot study is being conducted to treat patients who have a certain type of malignancy (lymphoid or myeloid) with immune effector cells after a T-cell depleted allogeneic hematopoietic cell transplantation (TCD HSCT). This study is designed to see whether an investigational cellular product of immune cells obtained from a donor's cells that have been treated so that the type of cells that can lead to graft vs host disease have been removed can be safely administered. These cell products are administered following the initial stem cell transplant to assess the effect and improvement on minimal residual disease status, infectious complication, progression-free and overall survival.

NCT ID: NCT05350072 Active, not recruiting - Sjogren Syndrome Clinical Trials

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NEPTUNUS-1
Start date: July 28, 2022
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)

NCT ID: NCT05349721 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

CARDINALS
Start date: May 15, 2022
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.

NCT ID: NCT05349422 Active, not recruiting - Blood Pressure Clinical Trials

Addressing Antihypertensive Medication Adherence Through EHR-enabled Teamlets in Primary Care

Start date: October 6, 2022
Phase: N/A
Study type: Interventional

The study team will conduct a cluster randomized control trial in 10 NYU primary care practices to assess the effectiveness and implementation of the multicomponent intervention on medication adherence and blood pressure control for patients who are non-adherent to antihypertensive medications.